Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET

Producción científica: Article › revisión exhaustiva

26 Citas (Scopus)

Resumen

Increased abundance of polo-like kinase 1 (PLK1) is observed in various tumor types, particularly in lung adenocarcinoma (LUAD). Here, we found that PLK1 accelerated the progression of LUAD through a mechanism that was independent of its role in mediating mitotic cell division. Analysis of human tumor databases revealed that increased PLK1 abundance in LUAD correlated with mutations in KRAS and p53, with tumor stage, and with reduced survival in patients. In a mouse model of KRASG12D-driven, p53-deficient LUAD, PLK1 overexpression increased tumor burden, decreased tumor cell differentiation, and reduced animal survival. PLK1 overexpression in cultured cells and mice indirectly increased the expression of the gene encoding the receptor tyrosine kinase RET by phosphorylating the transcription factor TTF-1. Signaling by RET and mutant KRAS in these tumors converged to activate the mitogen-activated protein kinase (MAPK) pathway. Pharmacological inhibition of the MAPK pathway kinase MEK combined with inhibition of either RET or PLK1 markedly suppressed tumor growth. Our findings show that PLK1 can amplify MAPK signaling and reveal a potential target for stemming progression in lung cancers with high PLK1 abundance.

Idioma originalEnglish
Número de artículoeabj4009
PublicaciónScience Signaling
Volumen15
N.º754
DOI
EstadoPublished - oct 4 2022

Nota bibliográfica

Publisher Copyright:
Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.

Financiación

We thank G. de Cárcer (Spanish National Cancer Research Centre) and A. Kasinski (Purdue University) for providing the transgenic mice. This work was supported by NIH R01 CA157429 (to X.L.), R01 CA196634 (to X.L.), R01 CA264652 (to X.L.), and R01 CA256893 (to X.L.). This research was also supported by the Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center (P30CA177558).

FinanciadoresNúmero del financiador
Spanish National Cancer Research Centre
National Institutes of Health (NIH)R01 CA256893, R01 CA196634, R01 CA157429
National Childhood Cancer Registry – National Cancer InstituteR01CA264652
Purdue Climate Change Research Center, Purdue University
University of Kentucky Markey Comprehensive Cancer CenterP30CA177558

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Biology
    • Cell Biology

    Huella

    Profundice en los temas de investigación de 'The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET'. En conjunto forman una huella única.

    Citar esto